残胃癌完成性胃切除术后新型预后预测模型的开发与国际多中心验证
本研究针对残胃癌患者淋巴结检查数常不足、TNM分期预后能力有限的问题,利用148例连续患者开发了5年总生存预测模型。
要点
- 模型纳入肿瘤浸润深度、转移淋巴结数、远处转移和手术时间四个独立预后因素。
- 模型在不同淋巴结检查数(>15或≤15)患者中均表现可靠。
核心结论
- 利用临床实用信息开发的通用预测模型能准确判断残胃癌完成性胃切除术后5年总生存,且在国际数据集中优于TNM分期。
研究设计与样本
- 使用148例连续患者作为测试数据集开发5年总生存预测模型,模型系数基于Cox分析。
- 采用Bootstrap法和校准评估进行内部验证,并使用中国福建医科大学附属第一医院(n=46)和美国Mayo Clinic(n=20)两个外部队列验证。
主要发现
- 肿瘤浸润深度、转移淋巴结数、远处转移和手术时间是独立预后因素。
- 模型校准在预测5年生存方面准确,决策曲线分析显示模型获益更大。
- 外部验证中两个机构数据集的C-index和决策曲线分析均显示良好预后性能。
- 在不同淋巴结检查数(>15或≤15)患者分析中验证了模型可靠性。
临床怎么用
- 该模型可用于残胃癌完成性胃切除术后患者的5年总生存预测,辅助临床决策。
- 模型在不同淋巴结检查数情况下均适用,可弥补TNM分期在淋巴结检查不足时的局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Examined lymph node counts of remnant gastric cancer patients are often insufficient, and the prognostic ability of tumor-node-metastasis staging is therefore limited. This study aimed to create a simple and universally applicable prediction model for RGC patients after completion of gastrectomy. METHODS: A 5-year overall survival prediction model for remnant gastric cancer patients was developed using a test dataset of 148 consecutive patients. Model coefficients were obtained based on the Cox analysis of clinicopathological factors. Prognostic performance was assessed with the concordance index (C-index) and decision curve analysis. For internal validation, the bootstrap method and calibration assessment were used. The model was validated using 2 external cohorts from China (First Affiliated Hospital of Fujian Medical University, n = 46) and the United States (Mayo Clinic, n = 20). RESULTS: Depth of tumor invasion, number of metastatic lymph nodes, distant metastasis, and operative time were independent prognostic factors. Our model's C-index (0.761) showed better discriminatory power than that of the eighth tumor-node-metastasis staging system (0.714, P = .001). The model calibration was accurate at predicting 5-year survival. Decision curve analysis showed that the model had a greater benefit, and the results were also confirmed by bootstrap internal validation. In external validation, the C-index and decision curve analysis showed good prognostic performances in patient datasets from 2 participating institutions. Moreover, we verified the reliability of the model in an analysis of patients with different examined lymph node counts (>15 or ≤15). CONCLUSION: Utilizing clinically practical information, we developed a universally applicable prediction model for accurately determining the 5-year overall survival of remnant gastric cancer patients after completion of gastrectomy. Our predictive model outperformed tumor-node-metastasis staging in diverse international datasets regardless of examined lymph node counts.
引用
- Lu J, Zheng ZF, Zhou JF, et al. A novel prognosis prediction model after completion gastrectomy for remnant gastric cancer: Development and validation using international multicenter databases. Surgery. 2019. PMID: 31221436. doi:10.1016/j.surg.2019.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。